First precision T-cell engager for solid tumours enters the clinic
Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development. The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More